Product info
Main page :: Product info   ::   Measles vaccine

Measles vaccine

Measles vaccine, live

Dry (lyophilized) avian egg-derived measles vaccine is obtained from preparation of the attenuated strain (Leningrad-16 (L-16)) of measles virus (or its recombinant derivative Moskva-5 strain) cultured on the cells of Japanese quail primary fibroblast. The final product looks like a homogenous yellow-pink substance. Single dose of the vaccine contains at least 1000 CID50 of measles virus and no more than 20 units of gentamycine sulphate or canamycine monosulphate.

Biological and immunological properties
Vaccine stimulates production of anti-measles antibodies by sero-test negative children in 21-28 days after immunization. The product wholly meets the requirements of WHO.

Vaccine is designed for taking scheduled preventive or emergency measures against measles.
Planned vaccination is for children with no history of having measles. Vaccination is carried out repeatedly: at the age of 12-15 months, then at the age of 6. Children, who’s mothers are shown to be seronegative to the measles virus, have to be vaccinated at the age of 8 months and then according to the Immunization Schedule. The interval between sessions of vaccination must be at least 6 months. Emergency vaccinating is directed to the children older than 12 months of the age, adolescents and the adults who were in contact with patients sustained measles, but have no history of either measles or vaccination against measles infection. Vaccine to be injected within 72 hours after the patient contacted infected person for the first time.

Dosage and administration
Before usage, the vaccine has to be reconstituted with supplied solvent (0.5 ml of the solvent per single dose of the vaccine). Dry vaccine should be completely dissolved in three minutes. The liquid vaccine appears like a clear yellow-pink or colorless solution. Vaccine is injected subcutaneously with 0.5 ml dose, in the area below scapular or in upper-third shoulder’s area.

Side effect reactions
Some body temperature reactions may be observed on 6th to 18th days after the vaccination, including slight hyperemia of faucets, rhinitis and rarely – the cough or conjunctivitis, which are lasting for 1 - 3 days. Measles-like rash could be observed. There are no more than 2% of vaccinated persons, who show the rise of body temperature above 38.5єC. Weak skin hyperemia or edema might be observed too. They are resolved in 1 - 3 days, usually without any particular treatment. General complications due to vaccine are extremely rare (they include convulsive reactions, developed on 6 - 10 days after vaccination). Such complications are developed by children with abnormal allergic status, in background of higher body temperature and hypersensitivity symptoms appeared in 24-48 hours.
Note: History of febrile convulsions and body temperature rise above 38.5єC for post-vaccinating period may be considered as indications for treatment with antipyretics.

Vaccine is supplied as a kit with proper solvent; one ampoule contains 1 vaccinating dose per ampoule (vial).

Storage and transportation
The vaccine should be stored at the temperature 6  2єC in closed storage room, protected from moisture, kept away from light or other damages (by mould or rodents etc). Shelf life of the vaccine is 15 months. Shelf life of the supplied solvent – 3 years.